Literature DB >> 8068415

Mucosal infection of neonatal rhesus monkeys with cell-free SIV.

T W Baba1, J Koch, E S Mittler, M Greene, M Wyand, D Penninck, R M Ruprecht.   

Abstract

Although the mechanisms for maternal transmission are unknown, approximately half of the infants congenitally infected with the human immunodeficiency virus type 1 (HIV-1) seem to become infected late in gestation or during delivery. Previously, we have developed a rhesus monkey model for congenital infection by injecting cell-free simian immunodeficiency virus (SIV) directly into amniotic fluid. Our results suggested that fetal infection may have occurred via skin or mucous membrane exposure. Mucosal surfaces have also been implicated as a portal of virus entry by a study in which the presence of serosanguinous fluid in neonatal gastric aspirates correlated with an increased rate of HIV-1 transmission. To test whether cell-free virus could transverse intact neonatal mucosal surfaces, we administered SIVmac251 orally to four rhesus monkey neonates within 1 hr following cesarean section delivery. All four neonates developed viremia and were positive by cocultivation and PCR. Seroconversion occurred in three of the four neonates. The SIV dose given was within physiological range as shown by end-point dilution of virus stock and viremic plasma samples of juvenile rhesus monkeys. This primate model for mucosal transmission of cell-free virus features a high infection rate, thus making studies of mucosal immunity and the development of strategies to prevent intrapartum virus transmission possible.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8068415     DOI: 10.1089/aid.1994.10.351

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  23 in total

1.  Older rhesus macaque infants are more susceptible to oral infection with simian-human immunodeficiency virus 89.6P than neonates.

Authors:  Agnès-Laurence Chenine; Flavia Ferrantelli; Regina Hofmann-Lehmann; Mark G Vangel; Harold M McClure; Ruth M Ruprecht
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Quantitative MRI Measures in SIV-Infected Macaque Brains.

Authors:  Xiaodong Zhang; Chunxia Li
Journal:  J Clin Cell Immunol       Date:  2013

3.  Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.

Authors:  K K Van Rompay; M D Miller; M L Marthas; N A Margot; P J Dailey; D R Canfield; R P Tarara; J M Cherrington; N L Aguirre; N Bischofberger; N C Pedersen
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes.

Authors:  Agnès L Chenine; Nagadenahalli B Siddappa; Victor G Kramer; Gaia Sciaranghella; Robert A Rasmussen; Sandra J Lee; Michael Santosuosso; Mark C Poznansky; Vijayakumar Velu; Rama R Amara; Chris Souder; Daniel C Anderson; François Villinger; James G Else; Francis J Novembre; Elizabeth Strobert; Shawn P O'Neil; W Evan Secor; Ruth M Ruprecht
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

5.  Tackling HIV and AIDS: contributions by non-human primate models.

Authors:  Koen K A Van Rompay
Journal:  Lab Anim (NY)       Date:  2017-05-22       Impact factor: 12.625

6.  Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.

Authors:  R Hofmann-Lehmann; J Vlasak; R A Rasmussen; B A Smith; T W Baba; V Liska; F Ferrantelli; D C Montefiori; H M McClure; D C Anderson; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; H Katinger; G Stiegler; L A Cavacini; M R Posner; T C Chou; J Andersen; R M Ruprecht
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3.

Authors:  Pushpa Jayaraman; Tuofu Zhu; Lynda Misher; Deepika Mohan; LaRene Kuller; Patricia Polacino; Barbra A Richardson; Helle Bielefeldt-Ohmann; David Anderson; Shiu-Lok Hu; Nancy L Haigwood
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

9.  A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.

Authors:  Panagiotis Vagenas; Meropi Aravantinou; Vennansha G Williams; Edith Jasny; Michael Piatak; Jeffrey D Lifson; Andres M Salazar; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

Review 10.  The oral mucosa immune environment and oral transmission of HIV/SIV.

Authors:  Lianna F Wood; Ann Chahroudi; Hui-Ling Chen; Heather B Jaspan; Donald L Sodora
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.